Skip to main content
n this issue: Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions.

Pharmacology Watch: Dabigatran: An Oral Direct Thrombin Inhibitor